SCHEDULE: Baker Bros. Maintain 5.2% Stake in Cerus Corp.

Baker Bros. Advisors and its principals have filed an Amendment No. 12 to their Schedule 13G, disclosing a continued 5.2% beneficial ownership in Cerus Corporation as of September 30, 2025.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker collectively reported beneficial ownership of Cerus Corporation common stock.
• As of September 30, 2025, the aggregate amount beneficially owned by Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC is 10,008,345 shares, representing 5.2% of the class.
• Julian C. Baker and Felix J. Baker each beneficially own 10,028,209 shares, also representing 5.2% of the class.
• This ownership includes shares held by Baker Brothers Life Sciences, L.P. (4.8%) and 667, L.P. (0.4%), totaling 10,008,345 shares.
• Julian C. Baker and Felix J. Baker also directly hold 19,864 shares each.
• The percentage is based on 192,037,000 shares outstanding as of September 30, 2025, as reported in Cerus Corporation's Form 10-Q filed on November 6, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The continued significant beneficial ownership by Baker Bros. Advisors, a specialized life sciences investment firm, suggests ongoing confidence in Cerus Corporation. This stable institutional backing is generally viewed favorably by the market.

Positives

• Significant institutional investor (Baker Bros. Advisors), a prominent life sciences fund, maintains a substantial stake (5.2%) in Cerus Corporation, indicating continued confidence.
• The filing explicitly states the securities were acquired and are held in the ordinary course of business, not for control purposes, which can signal stability in the investment.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in the biotechnology/medical device sector, where Cerus Corporation operates. Baker Bros. Advisors is a prominent investor in the life sciences industry, and their sustained holding suggests ongoing belief in the sector's potential and Cerus's position within it.

Comparison to Industry Standards

• Baker Bros. Advisors is a well-known specialist investor in the life sciences sector, often taking significant stakes in companies like Cerus. Their continued holding of 5.2% is consistent with their strategy of long-term investment in promising biotech firms.
• A 5.2% stake is a substantial position for an institutional investor, often signaling a belief in the company's long-term prospects, similar to other significant institutional holdings seen in companies like Regeneron Pharmaceuticals (REGN) or Incyte Corporation (INCY) where specialized funds maintain core positions.

Stakeholder Impact

• Shareholders: The continued significant stake by a prominent institutional investor like Baker Bros. Advisors may instill confidence among other shareholders, potentially stabilizing or positively influencing the stock price.
• Management: The presence of a large, specialized investor can provide a degree of oversight and strategic input, potentially aligning management's interests with long-term shareholder value.

Key Dates

Recommendation

The filing is a routine update of a significant institutional ownership stake. While the continued presence of a respected investor like Baker Bros. Advisors is a positive signal, a Schedule 13G filing alone does not provide enough new fundamental information about Cerus Corporation's operational performance, financial health, or strategic direction to warrant a change in investment recommendation. Investors should 'hold' their current position and await further operational or financial updates from Cerus Corporation.

Keywords

Cerus Corporation, Baker Bros. Advisors, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, 157085101